Ventus Therapeutics U.S., Inc., a biotechnology company that builds upon proprietary expertise in structural biology, protein science and its unique ReSOLVE platform to design small molecule therapies across a number of therapeutic areas, is presenting data for its cyclic GMP-AMP synthase (cGAS) inhibitor program this month at two upcoming conferences: the 4th Inflammatory Skin Disease…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
